Relevant bibliographies by topics / Pre-Clinical tumor model

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Pre-Clinical tumor model'

Author: Grafiati
Published: 23 November 2024
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pre-Clinical tumor model.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pre-Clinical tumor model"

1

Buxbaum, C., A. Deo, B. Manobla, S. Levin, S. Ash, and Y. Shaked. "P16.07.A STUDYING NEUROBLASTOMA TUMOR MICROENVIRONMENT THROUGH A NOVEL PRE-CLINICAL MODEL." Neuro-Oncology 26, Supplement_5 (2024): v85. http://dx.doi.org/10.1093/neuonc/noae144.282.

Full text
Abstract:
Abstract BACKGROUND Neuroblastoma is a pediatric cancer that develops from neural crest cells. It has a dramatically variable course, ranging from very aggressive disease to benign differentiation and even spontaneous regression. In neuroblastoma, a crucial prognostic marker is the distinct cutoff at 18 months of age. Thus, children older than 18 months have a significantly worse prognosis than younger children. This age cutoff was studied thoroughly, but no explanatory mechanism has been found. All current pre-clinical research encompasses models in adult subjects while the development of tum
APA, Harvard, Vancouver, ISO, and other styles
2

Becker, William J., Purevdorj B. Olkhanud, and Jay A. Berzofsky. "Triple synergy between vaccine and checkpoint inhibitors in a pre-clinical tumor model." Journal of Immunology 208, no. 1_Supplement (2022): 118.14. http://dx.doi.org/10.4049/jimmunol.208.supp.118.14.

Full text
Abstract:
Abstract Despite advances in checkpoint inhibitor (CPI) therapy for cancer treatment, many malignancies remain resistant. Tumors deemed ‘cold’ based on lack of T cell infiltration into the stroma of the tumor show reduced potential for CPI therapy and finding the right combination to balance safety and efficacy is arduous. To study ways to circumvent these limitations, we used the preclinical mouse model of TC1 tumor cells resistant to conventional CPI therapy. The TC1 cells are transfected with oncogenes E6 and E7 of HPV16, and we designed a tumor-vaccine specific for an E7(43–77) peptide. We
APA, Harvard, Vancouver, ISO, and other styles
3

Ernst, Kati, Konstantin Okonechnikov, Laura von Soosten, et al. "BIOL-07. DISTINCTIVE FEATURES OF HIGH-GRADE GLIOMA MOUSE MODELS REVEALED BY SINGLE-NUCLEUS RNA-SEQUENCING GUIDE PRE-CLINICAL MODEL SELECTION." Neuro-Oncology 25, Supplement_1 (2023): i7. http://dx.doi.org/10.1093/neuonc/noad073.026.

Full text
Abstract:
Abstract Glioma is the most common pediatric central nervous system tumor, with high-grade gliomas (HGG) having one of the worst prognoses of all human cancers. In order to develop better diagnostics and therapies, it is essential to use faithful disease models. Currently, highly passaged patient-derived xenograft (PDX) models are most widely used in preclinical studies, although alternative immunocompetent models are becoming increasingly available. Here, we compare several in vivo glioma models on a single-cell level and investigate their similarity to primary human tumors. Single-nucleus se
APA, Harvard, Vancouver, ISO, and other styles
4

Ahmed, Eman N., Lauren C. Cutmore, and John F. Marshall. "Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells." Cancers 16, no. 18 (2024): 3186. http://dx.doi.org/10.3390/cancers16183186.

Full text
Abstract:
Chimeric antigen receptor (CAR) T cells have revolutionized the treatment of hematological malignancies. Unfortunately, this improvement has yet to be translated into the solid tumor field. Current immunodeficient models used in pre-clinical testing often overestimate the efficacy of CAR T cell therapy as they fail to recapitulate the immunosuppressive tumor microenvironment characteristic of solid tumors. As CAR T cell monotherapy is unlikely to be curative for many solid tumors, combination therapies must be investigated, for example, stromal remodeling agents and immunomodulators. The evalu
APA, Harvard, Vancouver, ISO, and other styles
5

Klose, Johannes, Stefan Trefz, Tobias Wagner, et al. "Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model." PLOS ONE 14, no. 2 (2019): e0211916. http://dx.doi.org/10.1371/journal.pone.0211916.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Weeber, Fleur, Salo N. Ooft, Krijn K. Dijkstra, and Emile E. Voest. "Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery." Cell Chemical Biology 24, no. 9 (2017): 1092–100. http://dx.doi.org/10.1016/j.chembiol.2017.06.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lulu, Amanda M., Dustin A. Cobb, Nagyeong Park, Lixia Liu, and Daniel W. Lee. "Abstract 6096: Acquired CAR-T therapy resistance in a pre-clinical model of pediatric rhabdomyosarcoma minimal residual disease." Cancer Research 85, no. 8_Supplement_1 (2025): 6096. https://doi.org/10.1158/1538-7445.am2025-6096.

Full text
Abstract:
Abstract Introduction: Current treatments for relapsed/refractory or metastatic rhabdomyosarcoma (RMS) are ineffective. Integrin αvβ3 plays a role in progression, metastasis and neovascularization in several cancers. HER2 is expressed on a majority of RMS and contributes to progression and metastasis in other cancers. Our lab previously demonstrated the efficacy of HER2 and αvβ3 CAR Ts in controlling or eliminating pediatric brain tumors. CAR T therapies for solid tumors face numerous obstacles with limited clinical success. While bispecific CAR Ts can overcome heterogeneous antigen expression
APA, Harvard, Vancouver, ISO, and other styles
8

Serritella, Anthony V., Pablo Saenz-Lopez Larrocha, Payal Dhar, et al. "The Human Soluble NKG2D Ligand Differentially Impacts Tumorigenicity and Progression in Temporal and Model-Dependent Modes." Biomedicines 12, no. 1 (2024): 196. http://dx.doi.org/10.3390/biomedicines12010196.

Full text
Abstract:
NKG2D is an activating receptor expressed by all human NK cells and CD8 T cells. Harnessing the NKG2D/NKG2D ligand axis has emerged as a viable avenue for cancer immunotherapy. However, there is a long-standing controversy over whether soluble NKG2D ligands are immunosuppressive or immunostimulatory, originating from conflicting data generated from different scopes of pre-clinical investigations. Using multiple pre-clinical tumor models, we demonstrated that the impact of the most characterized human solid tumor-associated soluble NKG2D ligand, the soluble MHC I chain-related molecule (sMIC),
APA, Harvard, Vancouver, ISO, and other styles
9

Breen, Kevin, Tuesday Haynes, Masashi Watanabe, and Mark Gilbert. "Abstract 2663: Determining the role of tumor mutational burden in a pre-clinical model of glioblastoma." Cancer Research 84, no. 6_Supplement (2024): 2663. http://dx.doi.org/10.1158/1538-7445.am2024-2663.

Full text
Abstract:
Abstract Despite advances in care in many cancer types, patients with glioblastoma (GBM) have a grim prognosis of 15 to 21 months and unchanged standard therapy since 2005. These tumors have a profoundly immunosuppressive tumor immune microenvironment. Immunotherapy, including the checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4, has transformed the treatment of many cancers but has failed in trials of both newly diagnosed and recurrent GBM. Tumor mutational burden (TMB) has been proposed as a predictor of response to ICI treatment, presumably through an increase in neoantigens that can
APA, Harvard, Vancouver, ISO, and other styles
10

Longe, Harold O., Anupama Sinha, Douglas V. Faller, and Gerald V. Denis. "Telomere-Based Pre-Clinical Therapy of Human Lymphoid Malignancy in a SCID Xenograft Model." Blood 108, no. 11 (2006): 4761. http://dx.doi.org/10.1182/blood.v108.11.4761.4761.

Full text
Abstract:
Abstract We continue to develop and extend our novel adjuvant therapy approach to lymphoid malignancy. We supplement CHOP with DNA oligonucleotides that mimic the chromosomal telomere, which we call a “T oligo.” These agents are homologous to the 3′ overhang nucleotide sequence of telomeres and have previously been shown to have anti-tumor activity in animal models of malignant melanoma and breast cancer. They are currently being evaluated in melanoma and breast cancer patients. If introduced into human or murine normal, proliferating primary B cells or T cells, T oligo causes transient cell c
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pre-Clinical tumor model"

1

Chen, Liu Qi. "Development and Application of AcidoCEST MRI for Evaluating Tumor Acidosis in Pre-Clinical Cancer Models." Diss., The University of Arizona, 2014. http://hdl.handle.net/10150/323450.

Full text
Abstract:
Tumor acidosis is an important biomarker in cancer. We have developed a noninvasive imaging method, termed acidosis Chemical Exchange Saturation Transfer (acidoCEST) MRI to measure extracellular pH (pHe) in the tumor microenvironment. Chapter 1 introduces the importance of measuring tumor acidosis and presents various imaging modalities and their shortcoming to measure pHe. Chapter 2 describes the optimization of acidoCEST MRI for in vivo pHe measurement. The acidoCEST MRI protocol consists of a CEST-FISP acquisition and Lorentzian line shape fittings. We determined the optimal saturation time
APA, Harvard, Vancouver, ISO, and other styles
2

Macedo, Gonzales Rodney. "Development of therapeutic vaccine strategies and pre-clinical animal tumor models for head and neck cancers." Thesis, Paris 6, 2015. http://www.theses.fr/2015PA066269/document.

Full text
Abstract:
Les cancers des voies aéro-digestives supérieures, liés à la consommation d'alcool et de tabac mais également à l'HPV-16, ont un pronostic médiocre malgré les traitements actuels. Le développement de nouvelles stratégies innovantes dans des modèles précliniques adaptés est ainsi nécessaire. Nous avons préalablement développé une stratégie vaccinale ADN permettant l'auto-assemblage in vivo de pseudo-particules virales non infectieuses exprimant l'oncoprotéine E7 de l'HPV-16 (pVLP-E7). Nous avons notamment montré que l'injection de pVLP-E7 en intradermique (ID) était capable d'induire de bonnes
APA, Harvard, Vancouver, ISO, and other styles
3

Haagensen, Emma Joanne. "Pre-clinical evaluation of P13K and MEK inhibitor combinations in colorectal cancer tumour models." Thesis, University of Newcastle Upon Tyne, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.633014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Houel, Ana. "Étude de l’induction de structures lymphoïdes tertiaires, par virothérapie oncolytique, pour stimuler l’immunité antitumorale endogène." Electronic Thesis or Diss., Sorbonne université, 2024. http://www.theses.fr/2024SORUS232.

Full text
Abstract:
Les structures lymphoïdes tertiaires (TLS) sont des agrégats organisés de cellules immunitaires qui se développent dans les tissus non-lymphoïdes à la suite d'une inflammation chronique. Les TLS matures, dont l'organisation est proche de celle d'un ganglion, sont associées à un bon pronostic dans les cancers à tumeurs solides et servent de prédicteur efficace de la réponse des patients traités par immunothérapie. Notre objectif a été d'étudier la virothérapie oncolytique comme stratégie pour induire des TLS dans le microenvironnement tumoral (TME) afin d'intensifier les réponses antitumorales.
APA, Harvard, Vancouver, ISO, and other styles
5

Baker, Amanda F., Neale T. Hanke, Barbara J. Sands, Liliana Carbajal, Janet L. Anderl, and Linda L. Garland. "Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models." BioMed Central, 2014. http://hdl.handle.net/10150/610318.

Full text
Abstract:
BACKGROUND: Carfilzomib (CFZ) is a proteasome inhibitor that selectively and irreversibly binds to its target and has been approved in the US for treatment of relapsed and refractory multiple myeloma. Phase 1B studies of CFZ reported signals of clinical activity in solid tumors, including small cell lung cancer (SCLC). The aim of this study was to investigate the activity of CFZ in lung cancer models. METHODS: A diverse panel of human lung cancer cell lines and a SHP77 small cell lung cancer xenograft model were used to investigate the anti-tumor activity of CFZ. RESULTS: CFZ treatment inhibit
APA, Harvard, Vancouver, ISO, and other styles
6

Yeo, Syn Kok. "Investigating the therapeutic potential of targeting NF-kappaB p52 in pre-clinical models of breast cancer." Thesis, Cardiff University, 2012. http://orca.cf.ac.uk/26546/.

Full text
Abstract:
Apoptosis is an important process in normal mammary gland physiology and has been implicated in mammary gland involution. In breast cancer cells, apoptotic resistance is an acquired feature that can promote tumour growth and progression. In order to assess the importance of apoptosis in these processes, caspases were directly inhibited by conditional expression of baculovirus p35 protein, a pan-caspase inhibitor, in the mammary glands of mice (rtTA/p35 mouse model). Inhibition of caspases during the first phase of involution in rtTA/p35 mice increased the number of sloughed luminal bodies whic
APA, Harvard, Vancouver, ISO, and other styles
7

Valkenburg, Kenneth C. "Developing Pre-Clinical Mouse Models of Prostate Cancer| Deciphering the Roles of Tumor Suppressors Adenomatous Polyposis Coli and Smad4." Thesis, Van Andel Research Institute, 2017. http://pqdtopen.proquest.com/#viewpdf?dispub=10274873.

Full text
Abstract:
<p> There are approximately 230,000 new diagnoses of prostate cancer every year in the U.S., making prostate cancer the most diagnosed cancer in men. It is responsible for approximately 30,000 deaths per year, with only lung cancer taking more lives. An important distinction must be made in men with prostate cancer. The majority of men with prostate cancer have a relatively indolent form of the disease, meaning high survival rates (100% survival 5 years after diagnosis) and no invasion of the tumor to other organs. However, approximately 4% of men are diagnosed with an aggressive form of the d
APA, Harvard, Vancouver, ISO, and other styles
8

Semenchenko, Kostyantyn. "Development of tumour therapies : from target validation of TTLL12 to tests of a small molecule XRP44X in pre-clinical models of cancer." Thesis, Strasbourg, 2014. http://www.theses.fr/2014STRAJ107.

Full text
Abstract:
Les modifications post-traductionnelles de la tubuline sont des cibles attrayantes pour la thérapie du cancer. TTLL12 est impliqué dans la détyrosination de la tubuline, la triméthylation de l’histone H4K20 et le cancer de la prostate. La thèse porte sur les effets de la surexpression de TTLL12 sur ces modifications à différents stades du cycle cellulaire et sur la sensibilité à des agents ciblant les microtubules. Les résultats montrent que TTLL12 affecte ces modifications indépendant du cycle cellulaire et réduit la sensibilité des cellules à paclitaxel. XRP44X est un nouvel inhibiteur de la
APA, Harvard, Vancouver, ISO, and other styles
9

Rand, Taylor Ann. "Effect of head up tilt on tumor perfusion in a pre-clinical model of prostate cancer." Thesis, 2018. http://hdl.handle.net/2097/39407.

Full text
Abstract:
Master of Science<br>Department of Kinesiology<br>Brad J. Behnke<br>Introduction: Prostate tumor arterioles lack functional smooth muscle and have a diminished myogenic response. Previous research has demonstrated an enhanced prostate tumor blood flow and oxygenation associated with the augmented mean arterial pressure during exercise. Thus, we tested the hypothesis that elevations in the heart-to-prostate tumor hydrostatic gradient via adoption of the 70˚ head-up tilt (HUT) body position would enhance perfusion of the prostate tumor, which may improve tumor oxygenation and radiation therapy o
APA, Harvard, Vancouver, ISO, and other styles
10

Veloso, Susana Caçador. "Development of 3D cancer cell models for pre-clinical research : evaluation of the tumour microenvironment in 3D stirred-systems." Master's thesis, 2014. http://hdl.handle.net/10316/28094.

Full text
Abstract:
Dissertação de mestrado em Biotecnologia Farmacêutica, apresentada à Faculdade de Farmácia da Universidade de Coimbra<br>Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most frequent type of lung cancer, constituting approximately 85% off all lung cancer cases. Despite intensive research for the development of anti-NSCLC drugs, the majority fail in clinical trials. The reasons could be due to absence of therapeutic action and/or due to side effects, which could not be predicted in vitro or in animal studies because they lack the hum
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Pre-Clinical tumor model"

1

Wang, Zihao, and Mengye Lyu. "Head and Neck Tumor Segmentation for MRI-Guided Radiation Therapy Using Pre-trained STU-Net Models." In Lecture Notes in Computer Science. Springer Nature Switzerland, 2025. https://doi.org/10.1007/978-3-031-83274-1_4.

Full text
Abstract:
Abstract Accurate segmentation of tumors in MRI-guided radiation therapy (RT) is crucial for effective treatment planning, particularly for complex malignancies such as head and neck cancer (HNC). This study presents a comparative analysis between two state-of-the-art deep learning models, nnU-Net v2 and STU-Net, for automatic tumor segmentation in pre-RT MRI images. While both models are designed for medical image segmentation, STU-Net introduces critical improvements in scalability and transferability, with parameter sizes ranging from 14 million to 1.4 billion. Leveraging large-scale pre-tr
APA, Harvard, Vancouver, ISO, and other styles
2

Audigier, Chloé, Tommaso Mansi, Hervé Delingette, et al. "Challenges to Validate Multi-Physics Model of Liver Tumor Radiofrequency Ablation from Pre-clinical Data." In Computational Biomechanics for Medicine. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-28329-6_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hou, H., N. Khan, and P. Kuppusamy. "Measurement of pO2 in a Pre-clinical Model of Rabbit Tumor Using OxyChip, a Paramagnetic Oxygen Sensor." In Advances in Experimental Medicine and Biology. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-55231-6_41.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

LaBella, Dominic. "Ensemble Deep Learning Models for Automated Segmentation of Tumor and Lymph Node Volumes in Head and Neck Cancer Using Pre- and Mid-Treatment MRI: Application of Auto3DSeg and SegResNet." In Lecture Notes in Computer Science. Springer Nature Switzerland, 2025. https://doi.org/10.1007/978-3-031-83274-1_21.

Full text
Abstract:
Abstract Automated segmentation of gross tumor volumes (GTVp) and lymph nodes (GTVn) in head and neck cancer using MRI presents a critical challenge with significant potential to enhance radiation oncology workflows. In this study, we developed a deep learning pipeline based on the SegResNet architecture, integrated into the Auto3DSeg framework, to achieve fully-automated segmentation on pre-treatment (pre-RT) and mid-treatment (mid-RT) MRI scans as part of the DLaBella29 team submission to the HNTS-MRG 2024 challenge. For Task 1, we used an ensemble of six SegResNet models with predictions fu
APA, Harvard, Vancouver, ISO, and other styles
5

Bishr, Mai K., and Ben O’Leary. "Mechanism of Action and Potential Use of SMAC Mimetics in Head and Neck Squamous Cell Carcinoma (HNSCC)." In Critical Issues in Head and Neck Oncology. Springer Nature Switzerland, 2025. https://doi.org/10.1007/978-3-031-84539-0_6.

Full text
Abstract:
Abstract Patients with head and neck squamous cell carcinoma (HNSCC) often present with locally advanced disease and despite aggressive treatment, relapse remains a significant challenge. Evasion of apoptosis, a mode of regulated cell death, has been implicated in treatment resistance and poor prognosis, partly via overexpression of inhibitor of apoptosis proteins (IAPs). Thus, therapeutic strategies targeting the anti-apoptotic machinery are being explored; one such strategy is the design of compounds that mimic the naturally occurring endogenous second mitochondria-derived activator of caspa
APA, Harvard, Vancouver, ISO, and other styles
6

Huang, Shao Hui, Revadhi Chelvarajah, Lessandra Y. S. Chee, Ezra Hahn, and Brian O’Sullivan. "The Evolving Landscape of Prognostic Factors in HPV-Related Oropharynx Cancer." In Critical Issues in Head and Neck Oncology. Springer Nature Switzerland, 2025. https://doi.org/10.1007/978-3-031-84539-0_15.

Full text
Abstract:
Abstract Risk-tailored approaches are the backbone of contemporary clinical research and treatment in oncology. Attention to risk-stratification model development, especially concerning the choice and emphasis of prognostic factors to include in a model, is essential to understanding prognosis and implementing strategies to advance treatment, e.g. selecting patients for differing treatments or strategies for exploration in clinical trials, including defining eligibility for trials and determining useful stratifications in the design of randomised controlled trials. Prognostic factors can be cl
APA, Harvard, Vancouver, ISO, and other styles
7

Rossmeisl, John H., Paulo A. Garcia, John L. Robertson, and Rafael V. Davalos. "Irreversible Electroporation for the Treatment of Brain Tumors: Pre-clinical Results in a Canine Model of Spontaneous Glioma." In IFMBE Proceedings. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-11128-5_201.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Abou-el-Enein, Mohamed, and Jordan Gauthier. "The Value of CAR-T-cell Immunotherapy in Cancer." In The EBMT/EHA CAR-T Cell Handbook. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_46.

Full text
Abstract:
AbstractThe development of genetically modified chimeric antigen receptor (CAR) T-cells to target cancer by conferring tumour antigen recognition has tremendously improved the fight against the disease and broadened treatment options for haematological malignancies (Elsallab et al. 2020b). However, in contrast to conventional drugs that patients can easily access, the implementation of CAR-T-cell therapy in routine clinical practice poses significant challenges. Access to CAR-T-cell products is currently limited to specific certified centres meeting the requirements set up by manufacturers and
APA, Harvard, Vancouver, ISO, and other styles
9

Bellone, Matteo, Sara Martina Parigi, and Elena Jachetti. "Pre-clinical evaluation of immunotherapy: The case for prostate cancer and the TRAMP model." In Tumor Immunology and Immunotherapy. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199676866.003.0012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Nguyen, Quynh T. N., Phuc T. Phan, Shwu-Jiuan Lin, et al. "Machine-Learning Based Risk Assessment for Cancer Therapy-Related Cardiac Adverse Events Among Breast Cancer Patients." In Studies in Health Technology and Informatics. IOS Press, 2024. http://dx.doi.org/10.3233/shti231116.

Full text
Abstract:
The study aims to develop machine-learning models to predict cardiac adverse events in female breast cancer patients who receive adjuvant therapy. We selected breast cancer patients from a retrospective dataset of the Taipei Medical University Clinical Research Database and Taiwan Cancer Registry between January 2004 and December 2020. Patients were monitored at the date of prescribed chemo- and/or -target therapies until cardiac adverse events occurred during a year. Variables were used, including demographics, comorbidities, medications, and lab values. Logistics regression (LR) and artifici
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pre-Clinical tumor model"

1

Smith, David J., Sean J. Josephson, and John C. Bischof. "A Model of Cryosurgical Destruction in AT-1 Prostate Tumor Based on Cellular Damage Mechanisms." In ASME 1997 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1997. http://dx.doi.org/10.1115/imece1997-1326.

Full text
Abstract:
Abstract The thermal history during a prostate cryosurgery is known to lead to different cooling rates, end-temperatures and end-times within a cryosurgical iceball. The tissue exposed to this range of thermal histories will experience thermally-induced biophysical events which affect cell viability (dehydration and intracellular ice formation. IIF), injury due solely to the temperature and time of exposure, and injury due to host response. In this study, the dehydration and IIF behavior of single AT-1 prostate cancer cells is experimentally measured, the biophysical parameters of water transp
APA, Harvard, Vancouver, ISO, and other styles
2

Nicolson, Fay, Bohdan Andreiuk, Eunah Lee, et al. "Optimization of Surface-Enhanced Spatially Offset Raman spectroscopy for Applications in Pre-Clinical Cancer Imaging." In Optical Molecular Probes, Imaging and Drug Delivery. Optica Publishing Group, 2025. https://doi.org/10.1364/omp.2025.om3e.3.

Full text
Abstract:
Achieving high selectivity and specificity in deep tumor imaging remains a critical challenge in optical imaging. While Raman spectroscopy has been widely used for imaging various tissues, its penetration depth in vivo is limited. Here, we introduce a novel approach that integrates Spatially Offset Raman Spectroscopy (SORS) with Surface Enhanced Raman Scattering (SERS) nanoparticles, known as Surface Enhanced Spatially Offset Raman Spectroscopy (SESORS), for in vivo imaging of deep-seated tumors. We detail the optimization of SORS instrumentation to improve signal-to-noise ratio (SNR), spectra
APA, Harvard, Vancouver, ISO, and other styles
3

Alley, Stephanie, Marion Tonneau, Damien Olivié, et al. "Assessing the impact of a pre-processing pipeline on a tumor localization model in prostate MRI within a large multi-institutional dataset (NRG-GU005)." In Clinical and Biomedical Imaging, edited by Barjor S. Gimi and Andrzej Krol. SPIE, 2025. https://doi.org/10.1117/12.3043835.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Leishman, Andrew, Olivia Harris, Jane Coates Ulrichsen, et al. "Abstract 1651: Profiling immune cells within the tumor microenvironment for optimal model selection for pre-clinical investigations." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-1651.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Turbitt, William J., Rachael M. Orlandella, Justin T. Gibson, and Lyse A. Norian. "Abstract 509: Acarbose, but not metformin, reduces tumor burden and improves intra-tumoral immune responses in a pre-clinical breast cancer model." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-509.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Turbitt, William J., Rachael M. Orlandella, Justin T. Gibson, and Lyse A. Norian. "Abstract 509: Acarbose, but not metformin, reduces tumor burden and improves intra-tumoral immune responses in a pre-clinical breast cancer model." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-509.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Paramathas, Sangeetha, Nathan Lewis, Tanya Guha, Zainab Motala, and David Malkin. "Abstract 2741: Assessing the utility of circulating tumor DNA as a surveillance tool for sarcomas and Li-Fraumeni syndrome using a pre-clinical model." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-2741.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Krishnamoorthy, Murali, Rahul Pal, Hannah Collins, and Anand T. N. Kumar. "Fast fluorescence lifetime imaging system for intraoperative surgical guidance." In Clinical and Translational Biophotonics. Optica Publishing Group, 2024. http://dx.doi.org/10.1364/translational.2024.tm5b.5.

Full text
Abstract:
We present a novel fast fluorescence lifetime imaging (FLT) system for high-resolution real-time intraoperative guidance, showcasing surgeries in pre-clinical mouse tumor models and ex− vivo clinical specimens for contrast-enhanced tumor identification.
APA, Harvard, Vancouver, ISO, and other styles
9

Princye, P. Hosanna, and Suzain Mehak. "Brain Tumor Detection Using Image Processing." In International Conference on Recent Trends in Computing & Communication Technologies (ICRCCT’2K24). International Journal of Advanced Trends in Engineering and Management, 2024. http://dx.doi.org/10.59544/itqb1258/icrcct24p112.

Full text
Abstract:
This proposed work presents an innovative artificial intelligence (AI) based algorithm for the accurate identification of brain tumors through medical imaging analysis. Brain tumors pose a significant health risk, and timely and precise diagnosis is crucial for effective treatment planning. Traditional diagnostic methods often require extensive manual analysis and are subject to human error. In this context, our proposed algorithm leverages the capabilities of deep learning and image processing to enhance the efficiency and accuracy of brain tumor identification. The algorithm utilizes a convo
APA, Harvard, Vancouver, ISO, and other styles
10

Torres-Dominguez, Lino E., Lina S. Franco, Mario Abrantes, et al. "Abstract PR008: Armed Myxoma virus demonstrates therapeutic activity in pre-clinical xenograft models." In Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; October 19-20, 2020. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/2326-6074.tumimm20-pr008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pre-Clinical tumor model' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography